If as a holding company, AMBS is not intent on sel
Post# of 30028
Would not a JV or series of licensings be prudent to allow for revenue recognition and create intrinsic value for both the company and build greater shareholder value?
Quote:
"The Company expects to commercialize LymPro in the second half of 2014 under CLIA in Alzheimer’s disease, one of the largest and most underserved markets in the world ($200B+ in the US alone, $500B+ worldwide) where we will seek to fulfill the key unmet medical need of early diagnosis. While CLIA will not allow the Company to generate the revenues that a full FDA approval eventually will, we believe there is an opportunity to generate meaningful revenues that will offset development costs in other areas until such a point where we are able to realize revenue generation in other categories..."
See more at: http://www.thechairmansblog.com/amarantus-bio...0SuG3.dpuf